We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+19.15%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.86B
AUM Growth
+$577M
Cap. Flow
+$413M
Cap. Flow %
22.17%
Top 10 Hldgs %
49.85%
Holding
103
New
20
Increased
27
Reduced
19
Closed
9

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$21.4M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$20.5M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$16M
4
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$14.4M
5
ADXS
Advaxis Inc
ADXS
+$13.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$68.3M
2
TVTX icon
Travere Therapeutics
TVTX
+$21.9M
3
UAM
Universal American Corp
UAM
+$12.1M
4
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$11.1M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 75.61%
2 Technology 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBSE
76
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$4.46M 0.24%
4,438
– –
CRDC
77
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$4.43M 0.24%
887,499
– –
EPRS
78
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$4.42M 0.24%
775,000
– –
OSUR icon
79
OraSure Technologies
OSUR
$273M
$3.69M 0.2%
685,528
+635,528
+1,271% +$3.93M
NGNE icon
80
Neurogene
NGNE
$696M
$3.69M 0.2%
26,588
– –
ZSAN
81
DELISTED
Zosano Pharma Corporation
ZSAN
$3.52M 0.19%
693
– –
AIXC
82
AIxCrypto Holdings Inc
AIXC
$16.6M
$3.46M 0.19%
+6
New +$3.49M
CASM
83
DELISTED
CAS Medical Systems, Inc.
CASM
$3.35M 0.18%
2,618,296
– –
PHIO icon
84
Phio Pharmaceuticals
PHIO
$12.1M
$3M 0.16%
10
+8
+400% +$2.69M
APYX icon
85
Apyx Medical
APYX
$165M
$2.64M 0.14%
947,400
-63,600
-6% -$175K
TRNX
86
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$2.5M 0.13%
100,000
– –
UNIS
87
DELISTED
Unilife Corporation
UNIS
$2.47M 0.13%
115,000
– –
CDTX
88
DELISTED
Cidara Therapeutics
CDTX
$2.1M 0.11%
+7,500
New +$2.31M
TEAR
89
DELISTED
TearLab Corporation
TEAR
$1.85M 0.1%
91,450
– –
MDWD icon
90
MediWound
MDWD
$183M
$847K 0.05%
+17,124
New +$745K
CAPR icon
91
Capricor Therapeutics
CAPR
$1.14B
$596K 0.03%
11,800
-58,788
-83% -$3.69M
SSKN
92
DELISTED
Strata Skin Sciences
SSKN
$441K 0.02%
7,673
-4,085
-35% -$333K
TRIV
93
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$32K ﹤0.01%
+6,032
New +$42.8K
CARM
94
DELISTED
Carisma Therapeutics
CARM
– –
-48,303
Closed -$8.62M
CNMD icon
95
CONMED
CNMD
$1.29B
– –
-97,657
Closed -$4.93M
TNDM icon
96
Tandem Diabetes Care
TNDM
$1.17B
– –
-10,196
Closed -$1.29M
TVTX icon
97
CALL
Travere Therapeutics
TVTX
$5.33B
– –
-500,000
Closed -$11.2M
GHDX
98
DELISTED
Genomic Health, Inc.
GHDX
– –
-75,000
Closed -$2.29M
ADYX
99
DELISTED
Adynxx Inc
ADYX
– –
-3,678
Closed -$1.15M
UAM
100
DELISTED
Universal American Corp
UAM
– –
-1,133,989
Closed -$12.1M
1 2 3
4
5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Broadfin Capital held 103 positions worth $1.86B, up 45% from $1.28B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital deployed $413M of net new capital in Q2 2015, opening 20 new positions and adding to 27 existing holdings. Its largest new stake was NEVRO CORP.: 419,559 shares worth $22.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 92% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $68.3M trimmed.

  • Broadfin Capital's largest Q2 2015 buy was NEVRO CORP.: 419,559 shares worth $22.6M.
  • Broadfin Capital added most to Pernix Therapeutics Holdings, Inc. in Q2 2015, an estimated $20.5M increase.
  • Broadfin Capital's biggest Q2 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $68.3M.
  • Broadfin Capital fully exited Universal American Corp in Q2 2015, selling an estimated $12.1M.
  • Broadfin Capital's ten largest holdings make up 50% of its $1.86B portfolio in Q2 2015.
  • Broadfin Capital opened 20 new positions and closed 9 in Q2 2015.
  • Broadfin Capital's portfolio value rose 45% quarter-over-quarter to $1.86B.

Based on Broadfin Capital's 13F filing for Q2 2015, filed 14 Aug 2015.